Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact
If envudeucitinib is approved, it will join a competitive oral psoriasis market flanked by drugs Icotyde, Otezla and Sotyktu.
The post Alumis snags set of Phase III psoriasis pill victories, but analysts lukewarm on impact appeared first on Clinical Trials Arena .